The genetics of transitional cell carcinoma: Progress and potential clinical application

BJU International

Volumn 84, Issue 4, 1999, Pages 412-427

  Knowles, M A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN;

BLADDER CANCER; CHROMOSOME 4P; CHROMOSOME 8P; CHROMOSOME 9Q; GENE DELETION; GENETICS; HETEROZYGOSITY LOSS; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0032822748     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1999.00217.x     Document Type: Review

References (136)

1. 1 Cutler SJ, Heney NM, Friedell GH. Longitudinal study of patients with bladder cancer: Factors associated with disease recurrence and progression. In Bonney WW, Prout GR Jr, eds, Bladder Cancer 1. Baltimore: Williams and Wilkins, 1982: 35-46
2. 2 Melamed MR, Voutsa NG, Grabstald H. Natural history and clinical behavior of in situ carcinoma of the human urinary bladder. Cancer 1964; 17: 1533-45
3. 3 Koss LG. Mapping of the urinary bladder: its impact on the concepts of bladder cancer. Hum Pathol 1979; 10: 531-48
4. 4 Spruck CH, Ohneseit PF, Gonzalez-Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-8
5. 5 Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994; 54: 531-8
6. 6 Kallioniemi A, Kallioniemi O-P, Sudar D et al. Comparative genomic hybridization for molecular genetic analysis of solid tumors. Science 1992; 258: 818-21
7. 7 Kallioniemi A, Kallioniemi O-P, Citro G et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridisation. Genes Chromosomes Cancer 1995; 12: 213-9
8. 8 Richter J. Jiang F, Gorog JP et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997; 57: 2860-4
9. 9 Hovey RM, Chu L, Balazs M et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res 1998; 58: 3555-60
10. 10 Richter J, Beffa L, Wagner U et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridisation. Am J Pathol 1998; 153: 1615-21
11. 11 Malone PR, Visvinathan KV, Ponder BAJ, Shearer RJ, Summerhayes IC. Oncogenes and bladder cancer. Br J Urol 1985; 57: 664-7
12. 12 Fujita J, Nakayama H, Onoue H et al. Frequency of active ras oncogenes in human bladder cancers associated with schistosomiasis. Jpn J Cancer Res 1987; 78: 915-20
13. 13 Knowles MA, Williamson M. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 1993; 53: 133-9
14. 14 Fitzgerald JM, Ramchurren N, Rieger K et al. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 1995; 87: 129-33
15. 15 Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res 1991; 51: 4486-91
16. 16 Pratt CI, Kao C, Wu S-Q, Gilchrist KW, Oyasu R, Reznikoff CA. Neoplastic progression by FJ/ras at different steps of transformation in vitro of human uroepithelial cells. Cancer Res 1992; 52: 688-95
17. 17 Coombs LM, Pigott DA, Sweeney E et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63: 601-8
18. 18 Sato K, Moriyama M, Mori S et al. An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992; 70: 2493-8
19. 19 Sauter G, Moch H, Moore D et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993; 53: 2199-203
20. 20 Underwood M, Bartlett J. Reeves J, Gardiner S, Scott R, Cooke T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995; 55: 2422-30
21. 21 Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-ERBB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996: 155: 321-6
22. 22 Proctor AJ, Coombs LM, Cairns JP, Knowles MA. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene 1991; 6: 789-95
23. 23 Bringuier PP, Tamimi J, Schuuring E. Amplification of the chromosome 11q13 region in bladder tumours. Urol Res 1994; 21: 451
24. 24 Bringuier PP, Tamimi Y, Schuuring E, Schalken J. Expression of cyclin D1 and EMS1 in bladder tumours: relationship with chromosome 11q13 amplification. Oncogene 1996; 12: 1747-53
25. 25 Oya M, Schmidt B, Schmitz-Dräger BJ, Schulz WA. Expression of G1 →S transition regulatory molecules in human urothelial cancer. Jpn J Cancer Res 1998; 89: 719-26
26. 26 Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997; 75: 1788-92
27. 27 Kotake T, Saiki S, Kinouchi T, Shiku H, Nakayama E. Detection of the c-myc gene product in urinary bladder cancer. Jpn J Cancer Res 1990; 81: 1198-201
28. 28 Lipponen PK. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 1995; 175: 203-10
29. 29 Sauter G, Carroll P, Moch H et al. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol 1995; 146: 1131-9
30. 30 Deloukas P, Schuler GD, Gyapay G et al. A physical map of 30,000 human genes. Science 1998; 282: 744-6
31. 31 Reznikoff CA, Belair CD, Yeager TR et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996; 5: 571-84
32. 32 Zhou H, Zhong L, Kuo WL et al. Tumour amplified kinase STKIS/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20: 189-93
33. 33 Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-7
34. 34 Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-55
35. 35 Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell 1997; 88: 315-21
36. 36 Sidransky D, von Eschenbach A, Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706-9
37. 37 Habuchi T, Takahashi R, Yamada H et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993; 53: 3795-9
38. 38 Spruck CH, Rideout WM, Olumi AF et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 1993; 53: 1162-6
39. 39 Williamson MP, Elder PA, Knowles MA. The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer 1994; 9: 108-18
40. 40 Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991; 6: 2305-9
41. 41 Ishikawa J, Xu H-J, Hu S-X et al. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 1991; 51: 5736-43
42. 42 Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251-6
43. 43 Logothetis CJ, Xu H-J, Ro JY et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992; 84: 1256-61
44. 44 Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993; 53: 365-70
45. 45 Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53-9
46. 46 Sarkis AS, Zhang Z-F, Cordon-Cardo C et al. p53 nuclear overexpression and disease progression in Ta bladder carcinoma. Int J Oncol 1993; 3: 355-60
47. 47 Soini Y, Turpeenniemi-Hujanen T, Kamel D et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 1993; 68: 1029-35
48. 48 Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-64
49. 49 Cordon-Cardo C, Zhang X-F, Dalbagni G et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-21
50. 50 Cairns P, Tokino K, Eby Y, Sidransky D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 1994; 54: 1422-4
51. 51 Devlin J, Keen AJ, Knowles MA. Homozygous deletion mapping at 9p21 in bladder carcinoma delines a critical region within 2cM of IFNA. Oncogene 1994; 9: 2757-60
52. 52 Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene - two products - two pathways. Trends Biochem Sci 1998; 23: 291-6
53. 53 Kamb A, Gruis NA, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-40
54. 54 Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6
55. 55 Cairns P, Mao L, Merlo A et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415-7
56. 56 Spruck CH, Gonzalez-Zulueta M, Shibata A et al. p16 gene in uncultured tumours. Nature 1994; 370: 183-4
57. 57 Orlow I, Lacombe L, Hannon GJ et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995; 87: 1524-9
58. 58 Packenham JP, Taylor JA, Anna CH, White CM, Devereux TR. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol Carcinog 1995; 14: 147-51
59. 59 Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995; 4: 1569-77
60. 60 Balázs M, Carroll P, Kerschmann R, Sauter G, Waldman FM. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 1997; 19: 84-9
61. 61 Wu Q, Possati L, Montesi M et al. Growth arrest and suppression of tumorigenicity of bladder carcinoma cell lines induced by the p16/CDKN2 (p16INK4A, MTS1) gene and other loci on chromosome 9. Int J Cancer 1996; 65: 840-6
62. 62 Yeager TR, DeVries S, Jarrard DF et al. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev 1998; 12: 163-74
63. 63 Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-62
64. 64 Guldberg P, Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent. Cancer Res 1997; 57: 3660-3
65. 65 Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997; 57: 4736-8
66. 66 Cairns P, Evron E, Okami K et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16: 3215-8
67. 67 Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80: 904-8
68. 68 Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J Biol Chem 1998; 273: 13375-8
69. 69 Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive. Oncogene 1997; 14: 3059-66
70. 70 Kagan J, Liu J, Stein JD et al. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 1998; 16: 909-13
71. 71 Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993; 8: 1083-5
72. 72 Linnenbach AJ, Pressler LB, Seng BA, Simmel BS, Tomaszewski JE, Malkowicz SB. Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Human Mol Gen 1993; 2: 1407-11
73. 73 Ruppert JM, Tokino K, Sidransky D. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 1993; 53: 5093-5
74. 74 Keen AJ, Knowles MA. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 1994; 9: 2083-8
75. 75 Habuchi T, Devlin J, Elder PA, Knowles MA. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 1995; 11: 1671-4
76. 76 Simoneau AR, Spruck CH, Gonzalez-Zulueta M et al. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GASI and PTC mutationns. Cancer Res 1996; 56: 5039-43
77. 77 Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992; 326: 737-40
78. 78 Takahashi T, Habuchi T, Kakehi Y et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998; 58: 5835-41
79. 79 Miyao N, Tsai YC, Lerner SP et al. Role of chromosome 9 in human bladder cancer. Cancer Res 1993; 53: 4066-70
80. 80 Habuchi T, Yoshida O, Knowles MA. A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localisation of the candidate region within a single 840kb YAC. Hum Mol Genet 1997; 6: 913-9
81. 81 Czerniak B, Chaturvedi V, Li I, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: impli& cations for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999; 18: 1185-96
82. 82 Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, Fradet Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 1999; 18: 157-63
83. 83 Habuchi T, Luscombe M, Elder PA, Knowles MA. Structure and methylation-based silencing of a gene (DBCCRI) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 1998; 48: 277-88
84. 84 Nishiyama H, Takahashi T, Kakehi Y, Habuchi T, Knowles MA. Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary bladder cancer. Genes Chromosomes Cancer 1999; 18: 2657-61
85. 85 van Slegtenhorst M, de Hoogt R, Hermans C et al. Identification of the tuberous sclerosis gene TSCI on chromosome 9q34. Science 1997; 277: 805-8
86. 86 Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi Y, Knowles MA. Mutation of the 9q34 gene TSCI in bladder cancer. Oncogene 1999; in press
87. 87 McGarvey TW, Maruta Y, Tomaszewski JE, Linnenbach AJ, Malkowicz SB. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 1998; 17: 1167-72
88. 88 Knowles MA, Shaw ME, Proctor AJ. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsa& tellite polymorphisms. Oncogene 1993; 8: 1357-64
89. 89 Takle LA, Knowles MA. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 1996; 12: 1083-7
90. 90 Wagner U, Bubendorf L, Gasser TC et al. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 1997; 151: 753-9
91. 91 Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998; 185: 345-51
92. 92 Fujiwara Y, Emi M, Ohata H et al. Evidence for the presence of two tumor suppressor genes on chromo& some 8p for colorectal carcinoma. Cancer Res 1993; 53: 1172-4
93. 93 Macoska JA, Trybus TM, Benson PD et al. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res 1995; 55: 5390-5
94. 94 Eydmann ME, Knowles MA. Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. Cancer Genet Cytogenet 1997; 93: 167-71
95. 95 Elder PA, Bell SM, Knowles MA. Deletion of two regions on chromosome 4 in bladder carcinoma: definition of a critical 750kB region at 4p16.3. J. Oncogene 1994; 9: 3433-6
96. 96 Polascik TJ, Cairns P, Chang WYH, Schoenberg MP, Sidransky D. Distinct regions of allelic loss on chromo& some 4 in human primary bladder carcinoma. Cancer Res 1995; 55: 5396-9
97. 97 Bell SM, Shaw M, Jou YS, Myers RM, Knowles MA. Identification and characterization of the human homol& ogue of SH3BP2. An SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer. Genomics 1997; 44: 163-70
98. 98 Fearon ER, Feinberg AP, Hamilton SH, Vogelstein B. Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 1985; 318: 377-80
99. 99 Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990; 50: 44-7
100. 100 Shaw ME, Knowles MA. Deletion mapping of chromo& some 11 in carcinoma of the bladder. Genes Chromosomes Cancer 1995; 13: 1-8
101. 101 Preslt JC Jr. Reuter VE, Galan T. Fair WR, Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991; 51: 5405-9
102. 102 Brewster SF, Gingell JC, Browne S, Brown KW. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 1994; 70: 697-700
103. 103 Chang WY-H, Cairns P, Schoenherg MP, Polascik TJ, Sidransky D. Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Res 1995; 55: 3246-9
104. 104 Lamm DL. Carcinoma in situ. Urol Clin N Am 1992; 19: 499-508
105. 105 Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995; 55: 5213-6
106. 106 Wagner U, Sauter G, Moch H et al. Patterns of p53, erbB-2 and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 1995; 26: 970-8
107. 107 Chaturvedi V, Li L, Hodges S et al. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene 1997; 14: 2059-70
108. 108 Pycha A, Mian C, Haitel A, Hofbauer J, Wiener H, Marberger M. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997; 157: 2116-9
109. 109 Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999; 154: 721-7
110. 110 Bartlett JM, Watters AD, Ballantyne SA, Going JJ, Grigor KM, Cooke TG. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br J Cancer 1998; 77: 2193-8
111. 111 Harnden P, Mahmood J, Southgate J. Cytokeratin 20 expression redefines uroepithelial papillomas of the blad& der. Lancet 1999; 353: 974-7
112. 112 Lunec J, Challen C, Wright C, Mellon K, Neal DE. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet 1992; 339: 439-40
113. 113 Xu X, Stower MJ, Reid IN, Garner RC, Burns PA. Molecular screening of multifocal transitional cell carci& noma of the bladder using p53 mutations as biomarkers. Clin Cancer Res 1996; 2: 1795-800
114. 114 Sakurada A, Suzuki A, Sato M et al. Infrequent genetic alterations of the pten/mmac1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 1997; 88: 1025-8
115. 115 Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture microdissection. Science 1996; 274: 998-1001
116. 116 Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet 1998; 14: 272-6
117. 117 Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-7
118. 118 Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31
119. 119 Pomerantz J, Schreiber-Agus N, Liegeois NJ et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-23
120. 120 Zhang Y, Xiong V, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: aRF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-34
121. 121 Haupt Y, Maya K, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9
122. 122 Bates S, Phillips AC, Clark PA et al. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395: 124-5
123. 123 Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998: 395: 125-6
124. 124 Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associ& ated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602
125. 125 Stein JP, Ginsberg DA, Grossfeld GD et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072-9
126. 126 Habuchi T, Kinoshita M, Yamada H et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994; 86: 1331-5
127. 127 Lianes P, Orlow I, Zhang Z-F et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86: 1325-30
128. 128 Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996; 2: 912-7
129. 129 Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090-4
130. 130 Grossman H. Liebert M, Antelo M et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998; 4: 829-34
131. 131 Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18: 1197-203
132. 132 Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 1998; 58: 5348-53
133. 133 Ooi A, Herz F, Ii S et al. Ha-ras codon 12 mutation in papillary tumors of the urinary bladder: a retrospective study. Int J Oncol 1994; 4: 85-90
134. 134 Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155: 321-6
135. 135 Orlando C, Sestini R, Vona G et al. Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J Urol 1996; 156: 2089-93
136. 136 Cairns P, Polascik TJ, Eby Y et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995; 1 1 1: 210-2